Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC trimmed its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 43.4% during the 4th quarter, Holdings Channel reports. The fund owned 1,555 shares of the specialty pharmaceutical company’s stock after selling 1,190 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Supernus Pharmaceuticals were worth $45,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Assenagon Asset Management S.A. acquired a new stake in Supernus Pharmaceuticals during the fourth quarter worth about $1,049,000. Vanguard Group Inc. grew its holdings in Supernus Pharmaceuticals by 0.5% in the third quarter. Vanguard Group Inc. now owns 6,072,180 shares of the specialty pharmaceutical company’s stock valued at $167,410,000 after purchasing an additional 28,711 shares during the period. Loomis Sayles & Co. L P grew its holdings in Supernus Pharmaceuticals by 8.6% in the third quarter. Loomis Sayles & Co. L P now owns 1,730,269 shares of the specialty pharmaceutical company’s stock valued at $47,703,000 after purchasing an additional 136,964 shares during the period. Trust Point Inc. acquired a new stake in Supernus Pharmaceuticals in the fourth quarter valued at approximately $325,000. Finally, QRG Capital Management Inc. acquired a new stake in Supernus Pharmaceuticals in the third quarter valued at approximately $416,000.

Insider Activity

In other news, VP Padmanabh P. Bhatt sold 12,364 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $35.31, for a total value of $436,572.84. Following the transaction, the vice president now owns 8,570 shares in the company, valued at $302,606.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, VP Padmanabh P. Bhatt sold 3,884 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $32.99, for a total value of $128,133.16. Following the transaction, the vice president now owns 8,570 shares in the company, valued at $282,724.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 12,364 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $35.31, for a total value of $436,572.84. Following the completion of the transaction, the vice president now owns 8,570 shares in the company, valued at approximately $302,606.70. The disclosure for this sale can be found here. Insiders have sold a total of 35,739 shares of company stock worth $1,227,433 over the last quarter. 8.76% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Separately, Piper Sandler dropped their price objective on Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating on the stock in a report on Wednesday, February 28th.

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $29.40 on Monday. Supernus Pharmaceuticals, Inc. has a 12 month low of $21.99 and a 12 month high of $39.09. The stock’s 50 day moving average is $31.33 and its two-hundred day moving average is $28.54.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.39). The business had revenue of $164.30 million during the quarter, compared to analyst estimates of $155.03 million. Supernus Pharmaceuticals had a net margin of 0.22% and a return on equity of 0.14%. The firm’s revenue for the quarter was down 1.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.43 earnings per share. On average, analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.16 earnings per share for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.